Clinical trial

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing…

NCT00401830 · UCB Pharma, Industry · Completed

Key facts

NCT number NCT00401830
Title Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
Official title A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome
Lead sponsor UCB Pharma, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Fibromyalgia Syndrome
Intervention type Drug, Other
Interventions Lacosamide, Placebo
Enrollment 159
Start date Oct 1, 2006
Primary completion Feb 1, 2008
Completion Feb 1, 2008
First posted Nov 22, 2006
Last update posted Jul 18, 2018
Countries United States

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies